Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
Hs 578T
TNBC
Basal B
Triciribine
AKT
AKT
7472.074
uM
inf
inf
1.0500 1.0500 0.0000 0.0523
-0.0595
1.5922
MDA-MB-134-VI
HR+
Luminal
Epirubicin
TOP2
TOP
7877.017
uM
inf
inf
1.0500 1.0500 0.0000 0.1618
0.3038
0.6955
BT-20
TNBC
Basal A
Methotrexate
DHFR
Metabolism
5904.085
uM
inf
inf
1.0500 1.0500 0.0000 -0.0334
-1.4110
1.2247
HCC38
TNBC
Basal B
Trametinib
MEK
MAPK
9028.05
uM
inf
inf
1.0500 1.0500 0.0000 -0.0399
-2.6337
0.9299
CAMA-1
HR+
Luminal
Cetuximab
EGFR
ErbB
7805.018
uM
inf
inf
1.0500 1.0500 0.0000 -0.0217
-0.4906
1.1451
LY2
HR+
Luminal
L-779450
BRAF
MAPK
10816.149
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.4545
MDA-MB-231
TNBC
Basal B
PS-1145
IKK
NFKB
7504.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0441
-20.3886
1.6220
MDA-MB-361
HER2amp
Luminal
PS-1145
IKK
NFKB
7506.065
uM
inf
inf
1.0500 1.0500 0.0000 0.0433
0.1148
1.0475
Hs 578T
TNBC
Basal B
Purvalanol A
CDK1
CDK
7475.067
uM
inf
inf
1.0500 1.0500 0.0000 -0.0408
-9.2547
2.4078
LY2
HR+
Luminal
Erlotinib
EGFR
ErbB
7477.091
uM
inf
inf
1.0500 1.0500 0.0000 -0.0458
-19.0433
1.1485
LY2
HR+
Luminal
(Z)-4-Hydroxytamoxifen
ESR1
7865.016
uM
inf
inf
1.0500 1.0500 0.0000 0.0278
0.0148
1.8047
Hs 578T
TNBC
Basal B
Lapatinib
EGFR/HER2
ErbB
7472.098
uM
inf
inf
1.0500 1.0500 0.0000 -0.0197
-0.2479
1.5098
Hs 578T
TNBC
Basal B
Erlotinib
EGFR
ErbB
7473.091
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
2.3297
MCF 10F
NM
-
FTase Inhibitor I
Ftase
MAPK
12254.154
uM
inf
inf
1.0500 1.0500 0.0000 -0.0451
-13.9008
1.6307
LY2
HR+
Luminal
PS-1145
IKK
NFKB
7477.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.7891
HCC1806
TNBC
Basal A
Erlotinib
EGFR
ErbB
7450.091
uM
inf
inf
1.0500 1.0500 0.0000 -0.0008
0.1356
1.0419
LY2
HR+
Luminal
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7477.084
uM
inf
inf
1.0500 1.0500 0.0000 -0.0334
-0.0852
0.9476
SUM185PE
TNBC
Luminal
Cetuximab
EGFR
ErbB
10146.124
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.9296
BT-20
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
5902.095
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
1.0245
BT-20
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
10385.095
uM
inf
inf
1.0500 1.0500 0.0000 0.0010
0.0617
0.7986
SUM159PT
TNBC
Basal B
PS-1145
IKK
NFKB
7531.065
uM
inf
inf
1.0500 1.0500 0.0000 -0.0370
-7.5867
3.4461
SUM159PT
TNBC
Basal B
Ro 32-0432
PKC
PKC
10520.142
uM
inf
inf
1.0500 1.0500 0.0000 -0.0236
-0.3274
3.1766
MDA-MB-231
TNBC
Basal B
Methotrexate
DHFR
Metabolism
7504.084
uM
inf
inf
1.0500 1.0500 0.0000 -0.0371
-3.9735
1.8866
SUM1315MO2
TNBC
Basal B
Nilotinib
ABL
nRTK
12428.17
uM
inf
inf
1.0500 1.0500 0.0000 -0.0450
-2.6385
0.9724
Hs 578T
TNBC
Basal B
Baicalein
Lipoxygenase
Metabolism
7472.072
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
1.2269